Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Y Donath

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Nature Reviews. Drug Discovery|May 24, 2014
Targeting inflammation in the treatment of type 2 diabetes: time to startMarc Y Donath
Cell Metabolism|November 28, 2020
Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?Marc Y Donath
Diabetologia|February 13, 2016
Multiple benefits of targeting inflammation in the treatment of type 2 diabetesMarc Y Donath
The Journal of Clinical Investigation|October 17, 2022
Type 1 diabetes: what is the role of autoimmunity in β cell death?Marc Y Donath
Swiss Medical Weekly|July 18, 2012
Diabetes mellitus Type 2--the new face of an old ladyKatharina Timper, Marc Y Donath
Nature Medicine|November 3, 2014
A role for interleukin-22 in the alleviation of metabolic syndromeElise Dalmas, Marc Y Donath
Cell Metabolism|November 2, 2010
IL-1β activation as a response to metabolic disturbancesMarc Y Donath, Marianne Böni-Schnetzler
Nature Reviews. Immunology|January 15, 2011
Type 2 diabetes as an inflammatory diseaseMarc Y Donath, Steven E Shoelson
British Journal of Clinical Pharmacology|April 18, 2012
How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetesMarianne Böni-Schnetzler, Marc Y Donath
Diabetologia|December 25, 2014
Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetesJan A Ehses, Marc Y Donath
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Nature Reviews. Drug Discovery|May 24, 2014
Targeting inflammation in the treatment of type 2 diabetes: time to startMarc Y Donath
Cell Metabolism|November 28, 2020
Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?Marc Y Donath
Diabetologia|February 13, 2016
Multiple benefits of targeting inflammation in the treatment of type 2 diabetesMarc Y Donath
The Journal of Clinical Investigation|October 17, 2022
Type 1 diabetes: what is the role of autoimmunity in β cell death?Marc Y Donath
Swiss Medical Weekly|July 18, 2012
Diabetes mellitus Type 2--the new face of an old ladyKatharina Timper, Marc Y Donath
Nature Medicine|November 3, 2014
A role for interleukin-22 in the alleviation of metabolic syndromeElise Dalmas, Marc Y Donath
Cell Metabolism|November 2, 2010
IL-1β activation as a response to metabolic disturbancesMarc Y Donath, Marianne Böni-Schnetzler
Nature Reviews. Immunology|January 15, 2011
Type 2 diabetes as an inflammatory diseaseMarc Y Donath, Steven E Shoelson
British Journal of Clinical Pharmacology|April 18, 2012
How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetesMarianne Böni-Schnetzler, Marc Y Donath
Diabetologia|December 25, 2014
Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetesJan A Ehses, Marc Y Donath
Pageof 13